KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Pacira BioSciences (PCRX) Shares Outstanding (Weighted Average) (2016 - 2025)

Pacira BioSciences (PCRX) has 16 years of Shares Outstanding (Weighted Average) data on record, last reported at $44.6 million in Q4 2025.

  • For Q4 2025, Shares Outstanding (Weighted Average) fell 3.63% year-over-year to $44.6 million; the TTM value through Dec 2025 reached $44.6 million, down 3.63%, while the annual FY2025 figure was $44.6 million, 3.63% down from the prior year.
  • Shares Outstanding (Weighted Average) reached $44.6 million in Q4 2025 per PCRX's latest filing, up from $44.0 million in the prior quarter.
  • Across five years, Shares Outstanding (Weighted Average) topped out at $46.5 million in Q1 2024 and bottomed at $43.8 million in Q1 2021.
  • Average Shares Outstanding (Weighted Average) over 5 years is $45.4 million, with a median of $45.7 million recorded in 2022.
  • Peak YoY movement for Shares Outstanding (Weighted Average): increased 4.79% in 2021, then dropped 4.82% in 2025.
  • A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $44.3 million in 2021, then rose by 2.84% to $45.5 million in 2022, then rose by 1.54% to $46.2 million in 2023, then rose by 0.05% to $46.2 million in 2024, then decreased by 3.63% to $44.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for Shares Outstanding (Weighted Average) were $44.6 million in Q4 2025, $44.0 million in Q3 2025, and $45.9 million in Q2 2025.